Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
MaxCyte, Inc. Market Cap
The MaxCyte, Inc. (MXCT) share price is expected to decrease by 100% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered MXCT. Price targets range from $ at the low end to $ at the high end. The current analyst consensus for MXCT is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
MaxCyte, Inc. has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that MaxCyte, Inc. will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of MXCT.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Jacob Johnson Stephens & Co. | Overweight | $11 | Reiterates | Apr 23, 2024 |
| Mark Massaro BTIG | Buy | $8 | Maintains | Mar 13, 2024 |
| Jacob Johnson Stephens & Co. | Overweight | $11 | Reiterates | Mar 13, 2024 |
| Matt Hewitt Craig-Hallum | Buy | $7 | Initiates | Nov 29, 2023 |
| Jacob Johnson Stephens & Co. | Overweight | $12 | Reiterates | Oct 5, 2023 |
| Jacob Johnson Stephens & Co. | Overweight | $12 | Reiterates | Mar 28, 2023 |
| Mark Massaro BTIG | Buy | $11 | Maintains | Aug 15, 2022 |
Stifel | Buy | Initiates | Aug 24, 2021 | |
William Blair | Outperform | Initiates | Aug 24, 2021 | |
Cowen & Co. | Outperform | Initiates | Aug 24, 2021 | |
BTIG | Buy | Initiates | Aug 24, 2021 | |
Stephens & Co. | Overweight | Initiates | Aug 24, 2021 |
When did it IPO
N/A
Staff Count
143
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Maher Masoud
Market Cap
$412.9M
In 2023, MXCT generated $41.3M in revenue, which was a decrease of -6.72% from the previous year. This can be seen as a signal that MXCT's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 16 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Kamau will utilize MaxCyte's Flow Electroporation® technology and ExPERT™ platform to enhance its novel gene correction technology focused on homology-directed repair (HDR).
Why It Matters - MaxCyte's technology partnership with Kamau enhances gene correction capabilities, potentially leading to breakthroughs in gene therapies, which could drive stock value and market interest.
Thu, 05 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT) will present at the Virtual Craig-Hallum Capital Group Bioprocessing Conference on September 19th at 9:30 am ET.
Why It Matters - MaxCyte's participation in a key bioprocessing conference highlights its role in advancing cell-based therapeutics, potentially attracting investor interest and impacting stock performance.
Wed, 07 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - MaxCyte, Inc. (NASDAQ:MXCT) held its Q2 2024 earnings call on August 6, 2024, featuring key executives and analysts from various financial institutions.
Why It Matters - MaxCyte's earnings call provides insights into financial performance, strategic direction, and market positioning, influencing investor sentiment and stock valuation.
Tue, 06 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - MaxCyte, Inc. (NASDAQ: MXCT) reported its Q2 2024 financial results and updated its 2024 guidance, focusing on advancements in cell therapeutics and bioprocessing applications.
Why It Matters - MaxCyte's financial results and updated guidance can influence stock performance and investor sentiment, indicating potential growth or challenges in the cell therapy market.
Tue, 06 Aug 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - MaxCyte, Inc. (MXCT) reported a quarterly loss of $0.09 per share, better than the expected loss of $0.14, compared to a loss of $0.10 per share in the same quarter last year.
Why It Matters - MaxCyte's smaller-than-expected loss indicates improving financial performance, potentially boosting investor confidence and driving stock price upward.
Wed, 17 Jul 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - MaxCyte (MXCT) has passed the "Recent Price Strength" screening, indicating potential for profit for investors interested in actively moving stocks.
Why It Matters - MaxCyte's recent price strength indicates strong momentum, potentially attracting investors seeking profitable opportunities in trending stocks.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
